Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enhanced umbilical cord adherent stem cell - CHA Biotech

Next Previous
Drug Profile

Enhanced umbilical cord adherent stem cell - CHA Biotech

Alternative Names: CHAMS 201-CD; CHAMS 201-GR; CHAMS-210; CordSTEM-ARDS; CordSTEM-AS; CordSTEM-CD; CordSTEM-COVID; CordSTEM-DD; Cordstem-ST; CordSTEM®; Human umbilical cord derived mesenchymal stem cell therapy - CHA Biotech

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CHA Bio & Diostech
  • Class Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cartilage disorders; Gingival recession; Intervertebral disc degeneration; Stroke
  • Phase I Primary ovarian insufficiency
  • Discontinued Female genital diseases; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 28 May 2025 CHABiotech completes a phase I trial in Primary ovarian insufficiency (In adults) in South Korea (Parenteral) (NCT06578039)
  • 12 Mar 2025 Discontinued - Preclinical for Female genital diseases in South Korea (Parenteral) as of March 2025 (CHA Bio & Diostech pipeline, March 2025)
  • 12 Mar 2025 Discontinued - Preclinical for SARS-COV-2 acute respiratory disease in South Korea (Parenteral) as of March 2025 (CHA Bio & Diostech pipeline, March 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top